• Users Online: 575
  • Home
  • Print this page
  • Email this page
RESEARCH ARTICLE
Year : 2022  |  Volume : 12  |  Issue : 2  |  Page : 55-59

Ozone gas applied through nebulization as adjuvant treatment for lung respiratory diseases due to COVID-19 infections: a prospective randomized trial


1 Edis Pharma Pharmaceutical Industry, Istanbul, Turkey
2 Health Science Univercity, Umraniye Training and Research Hospital, Istanbul, Turkey
3 Dr. Feriha Öz Emergency Hospital, İstanbul, Turkey
4 Pendik State Hospital, İsttanbul, Turkey
5 Health Science Univercity, Haydarpasa Training and Research Hospital, İstanbul, Turkey

Correspondence Address:
Çağrı Özcan
Health Science Univercity, Umraniye Training and Research Hospital, Istanbul
Turkey
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/2045-9912.326001

Rights and Permissions

The objective of this study was to provide lung disinfection by nebulizing ozone gas with distilled water and olive oil for patients who have clinical symptoms due to coronavirus disease 2019 (COVID-19). The study attempted to reduce the viral load of COVID-19 in the lungs of patients, to provide a faster response to medical treatment. Between August 2020 and September 2020, 30 patients who met the study criteria were prospectively evaluated. There were 2 groups with 15 patients in each group: patients in control group were not treated with ozone and only received standard COVID-19 treatment; patients in ozone group received lung disinfection technique with ozone and standard COVID-19 treatment. A statistically significant difference was found in the length of stay in hospital, change in C-reactive protein, polymerase chain reaction results after 5 days, and computed tomography scores between two groups. There was no statistically significant difference in D-dimer, urea, lactate dehydrogenase, lymphocyte, leukocyte, and platelet between two groups. According to the data, we think that the lung disinfection technique applied with ozone inhalation reduces the rate of pneumonia in COVID-19 patients and makes the patients respond faster to the treatment and become negative according to the polymerase chain reaction tests. The study was approved by the Ethical Committee of the Istanbul Medipol University Clinical Trials (approval No. 0011) on July 2, 2020.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed887    
    Printed22    
    Emailed0    
    PDF Downloaded86    
    Comments [Add]    

Recommend this journal